Phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors

J Cortes, K Tamura, DJ DeAngelo, J de Bono, D Lorente, M Minden, GL Uy, H Kantarjian, K Keating, K McEachern, K Vishwanathan, RE Godin, JE Pease, Emma Dean

    Research output: Contribution to conference › Abstract › peer-review

    Fingerprint

    Dive into the research topics of 'Phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science